Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 1
2022 1
2023 2
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.
Flores BN, Yu SB, Cohen IV, Fanok MH, Luan W, Maciuca RD, Sun LD, Tsai RM, Vissers M, Smits L, Bunte TM, Bakardjiev A, Balasundar S, Calvert MEK, Chin MY, Dobbins SK, Dowdle WE, Fang M, Heuberger JAAC, Ha CL, Huang F, Miyamoto T, Osipov M, Madrid San Martin L, Saund K, Tatarakis D, Vu AQ, Xiong C, Yeo GW, Groeneveld GJ, van den Berg LH, Dhuria S, Estrada AA, Jennings D, Sandmann T, Ho C, Scearce-Levie K, Yulyaningsih E, Walker AK, Di Paolo G, Kane LA, Troyer MD, Lewcock JW. Flores BN, et al. Among authors: bunte tm. Nat Commun. 2025 Aug 18;16(1):7690. doi: 10.1038/s41467-025-63031-y. Nat Commun. 2025. PMID: 40825784 Free PMC article. Clinical Trial.
Respiratory measurements, respiratory symptoms, and quality of life in ALS: results from the REVEALS study.
Murray D, Rooney J, Meldrum D, Al-Chalabi A, Bunte TM, Chiwera T, Choudhury M, Chio A, Fenton L, Fortune J, Maidment L, Manera U, McDermott CJ, Meyjes M, Tattersall R, Torrieri MC, Van Damme P, Vanderlinden E, Wood C, Van Den Berg LH, Hardiman O. Murray D, et al. Among authors: bunte tm. Amyotroph Lateral Scler Frontotemporal Degener. 2025 Aug;26(5-6):467-477. doi: 10.1080/21678421.2025.2471421. Epub 2025 Mar 6. Amyotroph Lateral Scler Frontotemporal Degener. 2025. PMID: 40047382 Free article.
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Benatar M, Hansen T, Rom D, Geist MA, Blaettler T, Camu W, Kuzma-Kozakiewicz M, van den Berg LH, Morales RJ, Chio A, Andersen PM, Pradat PF, Lange D, Van Damme P, Mora G, Grudniak M, Elliott M, Petri S, Olney N, Ladha S, Goyal NA, Meyer T, Hanna MG, Quinn C, Genge A, Zinman L, Jabari D, Shoesmith C, Ludolph AC, Neuwirth C, Nations S, Shefner JM, Turner MR, Wuu J, Bennett R, Dang H, Sundgreen C; ORARIALS-01 trial team. Benatar M, et al. Lancet Neurol. 2024 Jul;23(7):687-699. doi: 10.1016/S1474-4422(24)00134-0. Epub 2024 May 20. Lancet Neurol. 2024. PMID: 38782015 Clinical Trial.
International network for ALS research and care (INARC).
Foucher J, Bunte TM, Bertone V, Verschoor RL, Couillard M, Straub C, Genge A, Ingre C, van den Berg LH. Foucher J, et al. Among authors: bunte tm. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Nov;25(7-8):795-796. doi: 10.1080/21678421.2024.2362850. Epub 2024 Jun 3. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38829007 Free article.
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures.
Bakers JNE, de Jongh AD, Bunte TM, Kendall L, Han SS, Epstein N, Lavrov A, Beelen A, Visser-Meily JMA, van den Berg LH, van Eijk RPA. Bakers JNE, et al. Among authors: bunte tm. Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):500-507. doi: 10.1080/21678421.2021.2016838. Epub 2021 Dec 24. Amyotroph Lateral Scler Frontotemporal Degener. 2022. PMID: 34949141 Free article.
A randomized, double-blind, placebo-controlled phase 2 study to assess safety, tolerability, and efficacy of RT001 in patients with amyotrophic lateral sclerosis.
Weemering DN, Midei M, Milner P, Gopalakrishnan V, Kumar A, Dannenberg AJ, Bunte TM, Foucher J, Ingre C, Ķēniņa V, Rallmann K, van den Berg LH, van Eijk RPA. Weemering DN, et al. Among authors: bunte tm. Eur J Neurol. 2023 Dec;30(12):3722-3731. doi: 10.1111/ene.16020. Epub 2023 Aug 21. Eur J Neurol. 2023. PMID: 37550954 Clinical Trial.
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
Genge A, Cedarbaum JM, Shefner J, Chio A, Al-Chalabi A, Van Damme P, McDermott C, Glass J, Berry J, van Eijk RPA, Fournier C, Grosskreutz J, Andrews J, Bertone V, Bunte TM, Couillard M, Cummings C, Kittle G, Polzer J, Salmon K, Straub C, van den Berg LH. Genge A, et al. Among authors: bunte tm. Amyotroph Lateral Scler Frontotemporal Degener. 2024 May;25(3-4):382-387. doi: 10.1080/21678421.2024.2320880. Epub 2024 Feb 23. Amyotroph Lateral Scler Frontotemporal Degener. 2024. PMID: 38396337 Free article.